I do not agree in the slightest. Canada and other countries do have production capacity. It's a complex endeavour when it comes to vaccines. On top of that, vaccines in this case use messenger RNA technology, so things get even more complex. Even with the formula to manufacture the vaccine, a company would have a very hard time beginning production overnight. It would require co-operation; technological know-how would have to be shared.
The capacity to foster that transfer of know-how does not currently exist. Any attempt to co-operate, share information and allow the use of existing vaccine-making capacity, would likely meet with legal challenges under the TRIPS Agreement or intellectual property provisions. It is a serious problem.
Now, we have tools to increase production, stem the pandemic and ensure Canadian companies have access to a swifter economic recovery, but we are not using them under the pretext that intellectual property must be protected.